Interim phase 3 report suggests BBV152 COVID-19 vaccine is safe and protects against disease
Interim data from a phase 3 trial of BBV152, a COVID-19 vaccine developed in India, reports that two doses offer 77.8% protection against symptomatic COVID-19.
Nov 11, 2021
0
44